Format
Sort by
Items per page

Send to

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 4024

1.

High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.

Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH.

Br J Haematol. 2017 Apr;177(2):263-270. doi: 10.1111/bjh.14541. Epub 2017 Mar 24.

PMID:
28340281
2.

Evaluation of the characteristics of some plant polyphenols as molecules intercepting mitoxantrone.

Osowski A, Kasparek A, Wieczorek Z, Amarowicz R, Szabelski M.

Food Chem. 2017 Jul 15;227:142-148. doi: 10.1016/j.foodchem.2017.01.083. Epub 2017 Jan 18.

PMID:
28274414
3.

The nerve growth factor alters calreticulin translocation from the endoplasmic reticulum to the cell surface and its signaling pathway in epithelial ovarian cancer cells.

Vera CA, Oróstica L, Gabler F, Ferreira A, Selman A, Vega M, Romero CA.

Int J Oncol. 2017 Apr;50(4):1261-1270. doi: 10.3892/ijo.2017.3892. Epub 2017 Feb 28.

PMID:
28260038
4.

Selective reversal of BCRP-mediated MDR by VEGFR-2 inhibitor ZM323881.

Zhang YK, Zhang XY, Zhang GN, Wang YJ, Xu H, Zhang D, Shukla S, Liu L, Yang DH, Ambudkar SV, Chen ZS.

Biochem Pharmacol. 2017 May 15;132:29-37. doi: 10.1016/j.bcp.2017.02.019. Epub 2017 Feb 27.

PMID:
28242251
5.

[Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].

Boudin L, Chabannon C, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Gonçalves A.

Bull Cancer. 2017 Apr;104(4):332-343. doi: 10.1016/j.bulcan.2016.12.007. Epub 2017 Feb 16. French.

PMID:
28214007
6.

The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.

Heath G, Airody A, Gale RP.

Drugs. 2017 Mar;77(3):303-311. doi: 10.1007/s40265-017-0692-6. Review.

PMID:
28181178
7.

Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib.

Zhang GN, Zhang YK, Wang YJ, Barbuti AM, Zhu XJ, Yu XY, Wen AW, Wurpel JND, Chen ZS.

Pharmacol Res. 2017 May;119:89-98. doi: 10.1016/j.phrs.2017.01.024. Epub 2017 Jan 25.

PMID:
28131876
8.

Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.

Magnano L, Montoto S, González-Barca E, Briones J, Sancho JM, Muntañola A, Salar A, Besalduch J, Escoda L, Moreno C, Domingo-Domenech E, Estany C, Oriol A, Altés A, Pedro C, Gardella S, Asensio A, Vivancos P, Fernández de Sevilla A, Ribera JM, Colomer D, Campo E, López-Guillermo A.

Ann Hematol. 2017 Apr;96(4):639-646. doi: 10.1007/s00277-017-2920-2. Epub 2017 Jan 18.

PMID:
28101592
9.

Cobalt Chloride Induces Expression and Function of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Renal Proximal Tubular Epithelial Cell Line HK-2.

Nishihashi K, Kawashima K, Nomura T, Urakami-Takebayashi Y, Miyazaki M, Takano M, Nagai J.

Biol Pharm Bull. 2017;40(1):82-87. doi: 10.1248/bpb.b16-00684.

10.

Dismal outcome of therapy-related myeloid neoplasm associated with complex aberrant karyotypes and monosomal karyotype: a case report.

Tang YL, Chia WK, Yap EC, Julia MI, Leong CF, Salwati S, Wong CL.

Malays J Pathol. 2016 Dec;38(3):315-319.

11.

Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.

Wilkerson J, Abdallah K, Hugh-Jones C, Curt G, Rothenberg M, Simantov R, Murphy M, Morrell J, Beetsch J, Sargent DJ, Scher HI, Lebowitz P, Simon R, Stein WD, Bates SE, Fojo T.

Lancet Oncol. 2017 Jan;18(1):143-154. doi: 10.1016/S1470-2045(16)30633-7. Epub 2016 Dec 13.

PMID:
27979599
12.

Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.

Atwal M, Lishman EL, Austin CA, Cowell IG.

Mol Pharmacol. 2017 Jan;91(1):49-57. Epub 2016 Nov 10.

13.

Acute inflammatory skin reaction during neutrophil recovery after antileukemic therapy.

Roengvoraphoj M, Yan S, Lansigan F, Chapman MS, Danilov AV.

Cutis. 2016 Oct;98(4):E13-E15. No abstract available.

PMID:
27874889
14.

Cytoskeletal reorganization and cell death in mitoxantrone-treated lung cancer cells.

Pawlik A, Szczepanski MA, Klimaszewska-Wisniewska A, Gackowska L, Zuryn A, Grzanka A.

Acta Histochem. 2016 Oct;118(8):784-796. doi: 10.1016/j.acthis.2016.10.001. Epub 2016 Nov 3.

PMID:
27817864
15.

Mitoxantrone-Surfactant Interactions: A Physicochemical Overview.

Enache M, Toader AM, Enache MI.

Molecules. 2016 Oct 13;21(10). pii: E1356. Review.

16.

Synergistic Cytotoxic and Anti-invasive Effects of Mitoxantrone and Triterpene Saponins from Lysimachia ciliata on Human Prostate Cancer Cells.

Koczurkiewicz P, Kowolik E, Podolak I, Wnuk D, Piska K, Łabędź-Masłowska A, Wójcik-Pszczoła K, Pękala E, Czyż J, Michalik M.

Planta Med. 2016 Dec;82(18):1546-1552. Epub 2016 Oct 13.

PMID:
27737477
17.

Novel polyacrylate-based cationic nanoparticles for survivin siRNA delivery combined with mitoxantrone for treatment of breast cancer.

Arami S, Mahdavi M, Rashidi MR, Fathi M, Hejazi MS, Samadi N.

Biologicals. 2016 Nov;44(6):487-496. doi: 10.1016/j.biologicals.2016.09.005. Epub 2016 Oct 3.

PMID:
27712979
18.

Nanomedical strategy to prolong survival period, heighten cure rate, and lower systemic toxicity of S180 mice treated with MTX/MIT.

Song N, Zhao M, Wang Y, Hu X, Wu J, Jiang X, Li S, Cui C, Peng S.

Drug Des Devel Ther. 2016 Aug 30;10:2701-11. doi: 10.2147/DDDT.S113804. eCollection 2016.

19.
20.

Disease modifying therapies for relapsing multiple sclerosis.

Wingerchuk DM, Weinshenker BG.

BMJ. 2016 Aug 22;354:i3518. doi: 10.1136/bmj.i3518. Review.

PMID:
27549763

Supplemental Content

Support Center